Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by Strs Ohio

Strs Ohio lowered its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 15.2% during the fourth quarter, Holdings Channel reports. The fund owned 24,600 shares of the company’s stock after selling 4,400 shares during the quarter. Strs Ohio’s holdings in Arvinas were worth $1,012,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its stake in shares of Arvinas by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,374 shares of the company’s stock worth $27,000 after acquiring an additional 674 shares during the period. BluePath Capital Management LLC acquired a new stake in shares of Arvinas in the third quarter worth $28,000. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Arvinas in the fourth quarter worth $75,000. Exchange Traded Concepts LLC increased its stake in shares of Arvinas by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 5,746 shares of the company’s stock worth $237,000 after acquiring an additional 1,457 shares during the period. Finally, Sectoral Asset Management Inc. increased its stake in shares of Arvinas by 13.5% in the third quarter. Sectoral Asset Management Inc. now owns 7,010 shares of the company’s stock worth $138,000 after acquiring an additional 835 shares during the period. Institutional investors and hedge funds own 95.19% of the company’s stock.

Wall Street Analyst Weigh In

ARVN has been the topic of several analyst reports. Truist Financial restated a “buy” rating and set a $65.00 price target on shares of Arvinas in a research report on Monday, March 25th. HC Wainwright dropped their price target on shares of Arvinas from $90.00 to $87.00 and set a “buy” rating on the stock in a research report on Friday, April 12th. Barclays raised their price target on shares of Arvinas from $26.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Wedbush raised their price target on shares of Arvinas from $33.00 to $59.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. Finally, Leerink Partnrs restated an “outperform” rating on shares of Arvinas in a research report on Thursday, February 22nd. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Arvinas has an average rating of “Moderate Buy” and an average price target of $59.73.

Arvinas Stock Down 2.6 %

NASDAQ ARVN opened at $34.00 on Wednesday. Arvinas, Inc. has a 52 week low of $13.57 and a 52 week high of $53.08. The stock has a market capitalization of $2.32 billion, a PE ratio of -5.23 and a beta of 1.94. The firm has a 50 day moving average of $42.95 and a two-hundred day moving average of $34.39.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($1.15) by ($1.38). Arvinas had a negative return on equity of 70.24% and a negative net margin of 185.09%. The firm had revenue of ($43.10) million for the quarter, compared to analyst estimates of $38.91 million. During the same quarter last year, the firm earned ($1.56) EPS. On average, equities research analysts expect that Arvinas, Inc. will post -5.02 earnings per share for the current fiscal year.

Insider Transactions at Arvinas

In other news, insider Ronald Peck sold 1,699 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $79,937.95. Following the completion of the sale, the insider now owns 67,516 shares in the company, valued at approximately $3,176,627.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Ronald Peck sold 1,699 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $79,937.95. Following the completion of the sale, the insider now owns 67,516 shares in the company, valued at approximately $3,176,627.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Sean A. Cassidy sold 1,702 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $80,079.10. Following the completion of the sale, the chief financial officer now owns 181,916 shares of the company’s stock, valued at approximately $8,559,147.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,597 shares of company stock worth $404,489. 5.23% of the stock is currently owned by insiders.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.